Bigger data = better data: detect 7,000 proteins at once with high throughput to optimize biomarker discovery
Abstract
The ideal biomarkers are waiting to be revealed within the human proteome. Big data from many thousands of protein analytes leads to superior biomarker models across therapeutic areas. In this webinar, you will discover how machine learning can be harnessed to select the right targets and build the right models for your research. You will also learn how to develop models, identify and mediate clinical risk, and elevate your research with greater precision than ever.
Joe Gogain, PhD
Clinical R&D at SomaLogic
Joe Gogain is a Director of Clinical Research and Development at SomaLogic, Inc., where he works closely with collaborating partners developing diagnostic and prognostic proteomic applications. Joe is a biological scientist with molecular diagnostic and immunoassay development expertise. Joe has a proven track record of IVD product development under design control and experience in de novo 510(k) regulatory submission processes and requirements. Additionally, Joe has served as a director of national clinical trials for point-of-care diagnostic devices and has experience managing a variety of technicians, scientists and clinical operations personnel.
Bigger Data = Better Data: Detect 7,000 proteins at once with high throughput to optimize biomarker discovery
A webinar presented by Joe Gogain, PhD
More webinars
WebinarBoutique Webinar Aptamers with protein-like side chains as a versatile tool for high-content proteomics
Proteins, encoded in 20,000 genes in humans, do much of the work in biology. Measuring proteins, which change in response to various perturbations and represent targets for almost all drugs, offers insights about the health status of an organism. Since proteins operate in complex networks rather than in isolation, measuring multiple proteins simultaneously offers richer insights compared to single protein measurements.
WebinarUsing Proteomics To Advance Understanding of Alzheimer’s Disease
Limited understanding due to its complex pathophysiology and lack of definitive biomarkers currently constrains the diagnosis and treatment of Alzheimer’s disease (AD). But new research is uncovering dynamic brain changes during Alzheimer’s progression, offering potential therapeutic targets. This webinar explores how proteomics and systems biology can be integrated to elucidate AD pathology.
WebinarPredictive modeling and reliable biomarker discovery in clinical omics studies
High-content omic technologies coupled machine learning methods have transformed the biomarker discovery process. However, the translation of computational results into scalable clinical biomarkers remains challenging. A rate-limiting step is the rigorous selection of reliable biomarker candidates among a host of biological features. Drawing examples from real-world clinical omics studies, I will introduce Stabl, a general machine learning framework that identifies a sparse, reliable set of biomarkers by integrating noise injection and a data-driven signal-to-noise threshold into multivariable predictive modeling.